HUTCHMED's ORPATHYS® Plus TAGRISSO® Shows Survival Benefits in MET-Driven Lung Cancer
Event summary
- HUTCHMED's SAFFRON Phase III trial showed ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) significantly improved progression-free and overall survival in MET-driven EGFR-mutated lung cancer patients.
- The trial enrolled 338 patients across 230 centers in 29 countries, with primary endpoint being progression-free survival.
- ORPATHYS® plus TAGRISSO® is already approved in China for this indication based on the SACHI Phase III trial.
- AstraZeneca is the commercialization partner for ORPATHYS® and the developer of TAGRISSO®.
The big picture
HUTCHMED's positive SAFFRON trial results reinforce TAGRISSO® as a backbone therapy in EGFR-mutated lung cancer, addressing a critical unmet need for patients with MET-driven resistance. The data support global registrations, potentially expanding the reach of this combination therapy beyond China. This development comes as biopharmaceutical companies increasingly focus on biomarker-directed treatments to improve outcomes in precision oncology.
What we're watching
- Regulatory Pathways
- The pace at which global regulatory authorities will review and approve the ORPATHYS® plus TAGRISSO® combination for MET-driven EGFR-mutated lung cancer.
- Commercial Strategy
- How AstraZeneca and HUTCHMED will position this combination therapy in the competitive EGFR-mutated lung cancer market.
- Clinical Adoption
- Whether oncologists will widely adopt MET testing to identify patients suitable for this targeted therapy.
Related topics